Wendy Young, Ph.D.

Dr. Wendy Young is an Entrepreneur at MPM and BioImpact Capital, an affiliate manager of MPM.  She is the CEO of a newly formed, stealth portfolio company and currently serves on the Board of Directors of BioIntervene, an MPM portfolio company. She is a biotechnology, pharma, and life sciences executive and board advisor with more than 25 years of experience in the discovery and development of innovative new medicines for patients. Wendy has held key senior roles at Genentech and Johnson & Johnson Company.

Prior to joining MPM and BioImpact Capital, Wendy was the Senior Vice President at Genentech where she actively built and led the small molecule drug discovery organization.  Under her leadership, more than 25 clinical candidates, in the areas of oncology, immunology, neurology, and anti-infectives, progressed into development. Additionally, Wendy led the BTK discovery program and is co-inventor of fenebrutinib which is currently in Phase 3 trials for multiple sclerosis. Prior to joining Genentech, Wendy held roles of increasing scientific leadership at Celera Genomics and Scios, a J&J company.  Wendy is an inventor and/or author on more than 70 published patents and manuscripts.

Known for her strong passion and contributions within the scientific community, Wendy has been involved with the American Chemical Society (ACS) for 20 years. In 2017, she was elected as the ACS National Chair of the Medicinal Chemistry Division (MEDI), and she currently serves as an associate editor of The Journal of Medicinal Chemistry. In 2018, Wendy was inducted as an ACS Fellow for her lifelong service to chemistry, society and medicine, and in 2019 highlighted as “One of the Top 20 Women in Biopharma” by Endpoint News. In 2020 she was awarded the prestigious Earle B. Barnes Award for Leadership in Chemical Research Management.

Wendy earned her Ph.D. from Princeton University, having studied in the laboratories of Edward C. Taylor.  At Princeton, and in collaboration with Eli Lilly, Wendy worked on folate analogs as antitumor agents and Alimta® was an outcome of this collaboration. Thereafter, as an American Cancer Society Fellow, she performed post-doctoral studies in the laboratories of Samuel Danishefsky at Sloan-Kettering Cancer Center and was part of the team that completed the total synthesis of Taxol®.

 

Pete Smith, Ph.D.

Dr. Pete Smith is an Entrepreneur at MPM and BioImpact Capital, an affiliate manager of MPM. He is the CSO of a newly formed, stealth portfolio company.  Pete has over 30 years of industry experience and is a proven leader in early drug discovery and development having held key senior roles at Alnylam Pharmaceuticals, Moderna Therapeutics and Millennium Pharmaceuticals.

Prior to joining MPM and BioImpact Capital, Pete was Chief Early Development Officer at Alnylam Pharmaceuticals focusing on RNAi-based medicines in four therapeutic areas including genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system and ocular diseases.  Prior to Alnylam, Pete was SVP and head of R&D Non-Clinical at Moderna and served as co-head of R&D at Millennium where he worked for 13 years.  He has extensive experience in drug discovery and development across multiple therapeutic areas including oncology, inflammation, infectious Disease amongst others and technologies including new modalities such as mRNA and siRNA.  During his career, Pete has overseen the development of multiple therapeutics, such as Celebrex™, Inspra™, Velcade™, Entyvio™, Onpattro™, Givlarri™, Oxlumo™ and Vutrisiran.  Pete began his career with 17 years in industry at SmithKline, Merck, Searle/Monsanto and Pharmacia in roles of increasing responsibility.

Pete earned a Ph.D. in Pharmacology and Toxicology from the University of Arizona, and a B.S from Fairfield University.

Pankaj Bhargava, M.D.

Dr. Pankaj Bhargava is an Entrepreneur at MPM and BioImpact Capital, an affiliate manager of MPM. He is currently the CEO of a newly formed, stealth portfolio company. Pankaj is active in supporting MPM’s investment collaboration with Dana-Farber Cancer Institute (DFCI), after having previously served as an Attending Physician at DFCI for over a decade. In addition, Pankaj supports MPM’s relationships with its key strategic pharmaceutical partner. He is also interim Chief Medical Officer (CMO) at Aktis Oncology and serves on the board of Tizona Therapeutics, both portfolio companies.

Prior to joining MPM and BioImpact Capital, Pankaj served as Vice President and Head of the Oncology Therapeutic Area at Gilead Sciences where he was responsible for driving oncology strategy and execution across programs spanning preclinical development to post-marketing commitments. In this role, Pankaj was instrumental in building the Gilead oncology portfolio with key partnerships and transactions including the acquisition of Forty Seven, Inc. and immuno-oncology partnerships with Arcus Biosciences, Agenus, Tizona and Pionyr Therapeutics.

Pankaj has been involved in drug development over two decades, during which he oversaw several functions, including clinical research, clinical operations, pharmacovigilance, regulatory affairs and medical affairs. He previously served as Chief Medical Officer at Dicerna Pharmaceuticals where he focused on RNA therapeutics in oncology, rare diseases and liver diseases, and held roles with increasing responsibilities at Tioma Therapeutics (now ARCH oncology), Sanofi Oncology and AVEO Pharmaceuticals. Pankaj has filed multiple INDs and led global registration programs and regulatory filings leading to drug approvals in US, EU and other regions.

Pankaj earned his M.D. from the University of Delhi and completed his training in medical oncology and developmental therapeutics at Georgetown University and Lombardi Cancer Center. He also completed a post-doctoral fellowship in clinical pharmacology at Georgetown University and NIH, during which he was a visiting fellow at FDA. Pankaj previously served as an Assistant Professor at Harvard Medical School and Dana-Farber Cancer Institute (2004-2017), and currently serves as a Clinical Assistant Professor at University of California, San Francisco.

Matthew Roden, Ph.D.

Dr. Matthew (Matt) Roden is an Entrepreneur at MPM and BioImpact Capital, an affiliate manager of MPM. He is the CEO of portfolio company Aktis Oncology. Matt also serves on the Boards of Directors of iTeos Therapeutics (NASDAQ: ITOS) and NextPoint Therapeutics, both portfolio companies, and is an investment committee member of the Oncology Impact Funds, private/public funds focused on oncology as well as new modalities, managed by BioImpact Capital.

Prior to joining MPM and BioImpact Capital, Matt’s career spanned senior leadership in large pharma, the healthcare equity capital markets, and in basic science as an immunologist and structural biologist. Most recently, Matt was Senior Vice President and Head of Enterprise Strategy at Bristol Myers Squibb. In this role, Matt delivered the initial strategic plan for the company following its acquisition of Celgene. Earlier, he served as Head of Strategic Corporate Development, accountable for mergers and acquisitions, structured transactions, strategic equity investing, and divestitures, and concurrently served as Head of Global BD Assessment, leading business development search and evaluation activities for all therapeutic categories. Matt served on the R&D Leadership Team representing external innovation and led teams on over 100 business development transactions that are cumulatively valued at over $125 billion, including Bristol Myers Squibb’s acquisition of Celgene, the largest acquisition in the healthcare industry to date.

Earlier, Matt was Head of Biotechnology Equity Research at UBS Investment Bank, he was a Senior Equity Analyst covering biotechnology at J.P. Morgan and Bank of America Merrill Lynch and was an Associate at Credit Suisse First Boston. In addition to his research coverage of the biotech sector, Matt and his teams provided equity research diligences and investor engagement on 24 equity offerings totaling $3.3bn in initial value from 2005-2016. Matt has also served in advisory or Board capacities to several organizations, including biotechnology companies, investment funds, BIO, BioNJ, and the State of New Jersey.

Matt earned a Ph.D. from the Albert Einstein College of Medicine, focusing on the structural biology of immune-relevant molecules. His graduate work was preceded by his pre-doctoral clinical research fellowship in immuno-oncology at the National Cancer Institute in Bethesda, Maryland. Matt holds a M.S. degree from Georgetown University and a B.S. from George Mason University.

Andrew M. Scharenberg, M.D.

Dr. Andrew M. Scharenberg is an Entrepreneur at MPM and BioImpact Capital, an affiliate manager of MPM. He is the founder and CEO of portfolio company Umoja Biopharma. Prior to founding Umoja, Andrew was an Attending Physician at Seattle Children’s Hospital, a Professor in the Department of Pediatrics, and an Adjunct Professor in the Department of Immunology at the University of Washington School of Medicine in Seattle.

While at Seattle Children’s/UW, Andrew co-directed the Program in Cell and Gene Therapy at Seattle Children’s Research Institute, working to translate cell and gene therapies for the treatment of inherited immunologic and blood diseases. This work led to the development of a program in engineered regulatory T-cells, partnered with Casebia Therapeutics for the purpose of developing a gene edited cell therapeutic for Type I diabetes and other inflammatory diseases. Previously, he was  the Chief Scientific Officer of Cellectis Therapeutics, where he initiated the development of an allogeneic CAR T-cell platform, and co-founder of Pregenen Inc., a gene editing and cell-signaling technology company that was acquired by bluebird bio in 2014. He also serves on the scientific advisory boards of Alpine Immune Sciences (chair), Generation Bio (chair), Genti Bio (chair), and Tessera Therapeutics.

Andrew earned his M.D. from the University of North Carolina School of Medicine, and then completed residency at the University of North Carolina Children’s Hospital and his fellowship in immunology at NIH and at the Division of Experimental Pathology, Beth Israel Hospital. Andrew received the American Pediatric Society/Society for Pediatric Research National Young Investigator Award in 2002. He is an active member of the American Society for Clinical Investigation and the American Pediatric Society.

Thomas M. Barnes, Ph.D.

Dr. Thomas (Tom) M. Barnes is an Entrepreneur at MPM and BioImpact Capital, an affiliate manager of MPM. He is the CEO of portfolio company Orna Therapeutics.  Tom is a veteran entrepreneur who has turned creative scientific visions into successful businesses for both startups and established organizations, having led platform-based research and drug discovery teams for over 20 years.  He has co-founded or helped launch several companies, including Intellia Therapeutics and Eleven Biotherapeutics.

Prior to joining MPM and BioImpact Capital, Tom was the Chief Scientific Officer of Intellia Therapeutics (NASDAQ: NTLA). During his tenure there, he built and established the discovery team, and helped raise over $300M over several financings, including Intellia’s IPO. He also led efforts to extend the reach of Intellia’s CRISPR platform into ex vivo delivery. He played a significant role as the main corporate spokesperson to lay and industry press, and to governmental and non-governmental organizations on the rapidly evolving and intensely followed CRISPR landscape.

Tom has wide-ranging knowledge of biological systems through his work across diverse platforms, including gene editing, genomics and gene discovery, small molecule drug repositioning, and protein engineering. Previously, as Vice President of Discovery at Eleven Biotherapeutics, Tom built the and led the research team in creating a novel chimeric cytokine antagonist, as well as novel half-life extension technologies for systemic and topical application. As Senior Vice President and site head of GeneLogic’s drug repositioning division, he oversaw technology platforms in metabolomics, toxicogenomics, gene expression informatics, and the genetics of drug metabolism and transport.

Tom received his Ph.D. from the University of Cambridge, and completed research fellowships at Harvard Medical School and McGill University.

Detlev Biniszkiewicz, Ph.D.

Dr. Detlev Biniszkiewicz is a Managing Director at MPM and Entrepreneur at BioImpact Capital, an affiliate manager of MPM. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role.

Prior to joining MPM and BioImpact Capital, Detlev was the President and CEO of Surface Oncology (NASDAQ: SURF), where he led its growth and transformation through to clinical-stage and its preparation for a public offering. Prior to Surface Oncology, he was Vice President of Strategy in AstraZeneca’s Oncology Unit and was part of the oncology leadership that developed Lynparza® and Tagrisso®, two innovative medicines that help thousands of patients suffering from cancer. His group transformed AstraZeneca’s Oncology pipeline through numerous licensing deals, clinical and academic collaborations, and external research. Detlev has also held multiple roles at Novartis including Global Head of Portfolio, where his group provided oversight of Novartis’ research and early development portfolio.

Detlev began his career at the Boston Consulting Group and performed his academic research at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology.

David Hallal

David Hallal currently serves as an MPM Advisor and Co-Founder, Chairman and CEO of ElevateBio, an MPM portfolio company that is a cell and gene therapy technology company that powers the design, manufacturing and development of transformative therapies. David is also Executive Chairman of AlloVir (NASDAQ: ALVR), an ElevateBio portfolio company developing innovative allogeneic, off-the-shelf, multi-virus specific T-cell immunotherapies. At ElevateBio and AlloVir, David has raised $1.6B in private and public financings that have led to multiple ongoing Phase 3 clinical trials at AlloVir and growing revenues at ElevateBio with its disruptive technology and manufacturing platform.

David brings more than 30 years of senior executive leadership experience in growing and operating several successful commercial stage biotechnology companies to his advisory role at MPM. He also serves as Chairman of the Board at iTeos Therapeutics (NASDAQ: ITOS), an MPM portfolio company, Chairman of the Board at Scholar Rock (NASDAQ: SRRK), and is Lead Independent Director of the Board of Directors at Seer (NASDAQ: SEER). Across ITOS, SRRK, and SEER, David has supported more than $2B in public and private financings resulting in multiple therapies in Phase 3 and earlier stages of clinical development as well as growing revenues at Seer with its disruptive proteomics platform.

Prior to MPM, he spent nearly 11 years at Alexion Pharmaceuticals where he played a central  role as CEO, Chief Operating Officer and Chief Commercial Officer in transforming the then pre-commercial company into a successful commercial company operating in 50 countries with greater than $3 billion in annual revenues.. As the CEO of Alexion, he grew revenues and expanded the pipeline from a single-product to a multi-product enterprise which eventually led to Alexion being acquired for $40 billion by Astra Zeneca. Prior to Alexion, from 1988-2006, David held leadership and executive positions at Amgen, Biogen and Eyetech where he was responsible for the commercial launches for multiple first-in-class therapies in hematology, oncology, nephrology, immunology, and ophthalmology.

David received his B.A. in Psychology from the University of New Hampshire.

Thomas Ebeling

Thomas Ebeling currently serves as an Advisor to BioImpact Capital, an affiliate manager of MPM.  He is the former CEO of ProSiebenSat.1 Media SE and Novartis Pharma. He currently serves on the supervisory board of Bayer AG and as the Chairman of Sivantos (Hearing Aids), Apleona (Facility Managment) and Remagine Ventures (Media and E Commerce). He is also a former board member of Lonza AG.

Mitchell H. Finer, Ph.D.

Dr. Mitchell (Mitch) H. Finer is an Entrepreneur at MPM and BioImpact Capital, an affiliate manager of MPM. He is the President of Research and Development at portfolio company ElevateBio and CEO of its subsidiary Life Edit Therapeutics. Mitch has been instrumental in founding, building and leading a number of portfolio companies. He is the founder and former CEO of Oncorus (NASDAQ: ONCR) and CODA Biotherapeutics. Mitch serves on several portfolio company boards, including CODA, ElevateBio, and Oncorus.

Prior to joining MPM and BioImpact Capital, Mitch was the CSO of bluebird bio. For three decades, he has focused on drug development utilizing the novel platforms of cell and gene therapy, cancer immunotherapy and regenerative medicine, and he has held several senior leadership roles in companies developing these therapies. Mitch has also served as CEO of Intracel Corporation and Genteric, Vice President Research for Cell Genesys and the Gencell division of Aventis Pharma (now Sanofi) and Senior Vice President of Development at Novacell (now Viacyte). He also successfully co-founded a retinal disease gene therapy company Avalanche Biotechnologies (now Adverum Biotechnologies) where he serves as a member of the board of directors.

Mitch has been named inventor on 15 issued U.S. patents in the field of engineered proteins, cells and viruses in the fields of gene therapy of orphan disease, regenerative medicine and immune oncology. He received his Ph.D. in Biochemistry and Molecular Biology from Harvard University and a B.S. in Biochemistry and Microbiology from the University of California at Berkeley. He completed a post-doctoral fellowship at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology.